Reform of pharma legislation: the debate on regulatory data protection
by Giuliana Miglierini As the definition of the final contents of many new pieces of the overall revision…
EMA’s pilot scheme for academic and non-profit development of ATMPs
by Giuliana Miglierini Advanced therapy medicinal products (ATMPs) are often developed by academic and non-profit organisations, because of…
Steps towards the final approval of the IP action plan
By Giuliana Miglierini The end of 2021 may see the final approval of many pieces of the new…